{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:12:38Z","timestamp":1793301158052,"version":"4.5.0"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Therapeutic drug monitoring of clozapine in children and adolescents has received insufficient attention. Calculation of concentration-to-dose (C\/D) ratios from trough steady-state concentrations estimate drug clearance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic electronic literature search was conducted in 3 article databases from inception until January 10, 2023, and articles reporting clozapine concentrations in children and adolescents were retrieved. The pharmacokinetic quality of the studies was assessed, and clozapine C\/D ratios were calculated using the sample mean clozapine dose and concentration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 37 articles of potential interest, only 7 reported clozapine trough and steady-state concentrations. After excluding case reports and a study confounded by fluvoxamine, 4 studies on psychosis from Europe and the United States were included. The clozapine C\/D ratios were similar to published adult values and ranged from 0.82 to 1.24 with a weighted mean of 1.08 ng\/mL per mg\/d. The weighted means were 334 mg\/d for the dose and 380 ng\/mL for the concentration. The stratified analysis of the weighted mean clozapine C\/D ratios from 2 studies showed lower values in 52 male (1.05 ng\/mL per mg\/d) than in 46 female (1.46 ng\/mL per mg\/d) children and adolescents, with values similar to those reported for European adult nonsmokers. Two female adolescents had high clozapine C\/D ratios (2.54 ng\/mL per mg\/d), an Asian American patient with borderline obesity and a patient with intellectual disability with low dosage (mean = 102 mg\/d) and concentration (mean = 55 ng\/mL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Reports on clozapine therapeutic drug monitoring in children and adolescents are limited in number and quality. Future studies should focus on basic pharmacokinetic issues, such as stratification by sex, smoking, and relevant comedications with inductive or inhibitory properties.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001154","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T13:06:49Z","timestamp":1701263209000},"page":"170-180","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["A Systematic Review of Clozapine Concentration\u2013Dose Ratio from Therapeutic Drug Monitoring Studies in Children and Adolescents Treated with Clozapine for Mental Disorders"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1515-2413","authenticated-orcid":false,"given":"Sara","family":"Jim\u00e9nez-Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Child and Adolescent Mental Health Unit, Virgen de Las Nieves University Hospital, Granada, Spain;"},{"name":"CTS-549 Research Group (Psychiatry and Neurosciences), Junta de Andaluc\u00eda, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1262-1627","authenticated-orcid":false,"given":"Manuel","family":"Gurpegui","sequence":"additional","affiliation":[{"name":"CTS-549 Research Group (Psychiatry and Neurosciences), Junta de Andaluc\u00eda, Spain;"},{"name":"Granada Center for Psychiatric Studies, Granada, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Charit\u00e9 Universit\u00e4tsmedizin, Berlin, Germany;"},{"name":"The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York;"},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra, Hempstead, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-2314","authenticated-orcid":false,"given":"Jose","family":"de Leon","sequence":"additional","affiliation":[{"name":"Mental Health Research Center, Eastern State Hospital, Lexington, Kentucky;"},{"name":"Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Ap\u00f3stol Hospital, University of the Basque Country, Vitoria, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[{"name":"The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York;"},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra, Hempstead, New York;"},{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Z\u00fcrich, Z\u00fcrich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000507638","article-title":"A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology","volume":"89","author":"de Leon","year":"2020","journal-title":"Psychother Psychosom"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review","volume":"11","author":"Wagner","year":"2021","journal-title":"Transl Psychiatry"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jpsychires.2020.02.026","article-title":"Clozapine in bipolar disorder: a systematic review and meta-analysis","volume":"125","author":"Delgado","year":"2020","journal-title":"J Psychiatr Res"},{"key":"R4-20250603","first-page":"36","article-title":"Retrospective review of clozapine use in children and adolescents","volume":"30","author":"Komaryk","year":"2021","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis","volume":"28","author":"Krause","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","article-title":"Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison","volume":"63","author":"Shaw","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/archpsyc.1996.01830120020005","article-title":"Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison","volume":"53","author":"Kumra","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/104454604773840490","article-title":"The off-label use of clozapine in adolescents with bipolar disorder, intermittent explosive disorder, or posttraumatic stress disorder","volume":"14","author":"Kant","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"43","DOI":"10.9758\/cpn.2019.17.1.43","article-title":"Clozapine in the treatment of aggression in conduct disorder in children and adolescents: a randomized, double-blind, controlled trial","volume":"17","author":"Ju\u00e1rez-Trevi\u00f1o","year":"2019","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.chc.2019.08.017","article-title":"Childhood-onset schizophrenia and early-onset schizophrenia spectrum disorders: an update","volume":"29","author":"Driver","year":"2020","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0706743717720197","article-title":"Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth","volume":"62","author":"Abidi","year":"2017","journal-title":"Can J Psychiatry"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1176\/appi.ps.201700162","article-title":"Addressing barriers to clozapine underutilization: a national effort","volume":"69","author":"Kelly","year":"2018","journal-title":"Psychiatr Serv"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/cap.2011.0136","article-title":"Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia","volume":"23","author":"Maher","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1089\/cap.2018.0036","article-title":"A retrospective multicenter evaluation of clozapine use in pediatric patients admitted for acute psychiatric hospitalization","volume":"28","author":"Steinauer","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/00004583-199406000-00005","article-title":"Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome","volume":"33","author":"Towbin","year":"1994","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/cap.2021.0092","article-title":"Clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis","volume":"32","author":"Adnan","year":"2022","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R18-20250603","first-page":"1","article-title":"Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia","volume":"29","author":"Schneider","year":"2014","journal-title":"Eur Psychiatry"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1097\/MJT.0000000000000894","article-title":"Off-label use of clozapine in children and adolescents-a literature review","volume":"26","author":"Rachamallu","year":"2019","journal-title":"Am J Ther"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"108236","DOI":"10.1016\/j.pharmthera.2022.108236","article-title":"Clozapine's multiple cellular mechanisms: what do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia","volume":"236","author":"de Bartolomeis","year":"2022","journal-title":"Pharmacol Ther"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00406-004-0505-2","article-title":"Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment","volume":"254","author":"de Leon","year":"2004","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","article-title":"Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia","volume":"20","author":"Horacek","year":"2006","journal-title":"CNS Drugs"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14656566.9.3.459","article-title":"Clozapine use in children and adolescents","volume":"9","author":"Gogtay","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","article-title":"A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients","volume":"12","author":"Schoretsanitis","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"183","DOI":"10.30773\/pi.2022.0293","article-title":"Reflections on the lack of consideration of ethnic ancestry to stratify clozapine dosing","volume":"20","author":"de Leon","year":"2023","journal-title":"Psychiatry Investig"},{"key":"R28-20250603","article-title":"A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status","author":"Reeves","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1124\/dmd.112.050278","article-title":"Which metabolites circulate?","volume":"41","author":"Loi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/JCP.0000000000001585","article-title":"Metabolite profiling of clozapine in patients switching versus maintaining treatment: a retrospective pilot study","volume":"42","author":"Kylles\u00f8","year":"2022","journal-title":"J Clin Psychopharmacol"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","article-title":"Overview of therapeutic drug monitoring","volume":"24","author":"Kang","year":"2009","journal-title":"Korean J Intern Med"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R33-20250603","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.07.002","article-title":"Exploring low clozapine C\/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: a literature review and a case series of 17 patients from 3 studies","author":"Ruan","year":"2023","journal-title":"Schizophr Res"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/acps.12673","article-title":"The significance of sampling time in therapeutic drug monitoring of clozapine","volume":"135","author":"Jakobsen","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00044011-199816010-00005","article-title":"A kinetic model for simultaneous fit of clozapine and norclozapine concentrations in chronic schizophrenic patients during long-term treatment","volume":"16","author":"Guitton","year":"1998","journal-title":"Clin Drug Investig"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/JCP.0000000000001018","article-title":"Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review","volume":"39","author":"Ruan","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/JCP.0000000000001125","article-title":"Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13","volume":"39","author":"Ruan","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.rpsm.2020.11.002","article-title":"Amerindians may need clozapine dosing similar to that of Asians","volume":"14","author":"Gonz\u00e1lez-Esquivel","year":"2021","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/JCP.0000000000001341","article-title":"European whites may need lower minimum therapeutic clozapine doses than those customarily proposed","volume":"41","author":"Schoretsanitis","year":"2021","journal-title":"J Clin Psychopharmacol"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2217\/pgs-2020-0015","article-title":"Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?","volume":"21","author":"Ruan","year":"2020","journal-title":"Pharmacogenomics"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","article-title":"Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service","volume":"16","author":"Jerling","year":"1994","journal-title":"Ther Drug Monit"},{"key":"R42-20250603","article-title":"Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition","volume":"31","author":"Schoretsanitis","year":"2023","journal-title":"Schizophrenia Res"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome p450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/JCP.0000000000000926","article-title":"The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial","volume":"38","author":"Diaz","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/JCP.0000000000001202","article-title":"Adding oral contraceptives to clozapine may require halving the clozapine dose: a new case and a literature review","volume":"40","author":"Schoretsanitis","year":"2020","journal-title":"J Clin Psychopharmacol"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/10600280211047864","article-title":"Inflammation suppresses patients' ability to metabolize cytochrome P450 substrate drugs","volume":"56","author":"White","year":"2022","journal-title":"Ann Pharmacother"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000506355","article-title":"Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24,000 days of clozapine treatment","volume":"89","author":"Ruan","year":"2020","journal-title":"Psychother Psychosom"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.rpsm.2022.06.001","article-title":"A Covid-19 outbreak in a Spanish long-term psychiatric hospital led to infections in 6 clozapine patients: elevations in their plasma clozapine levels","volume":"15","author":"Arrojo-Romero","year":"2022","journal-title":"Rev Psiquiatr Salud Ment (Engl Ed)"},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"e12384","DOI":"10.1111\/appy.12384","article-title":"Using therapeutic drug monitoring to personalize clozapine dosing in Asians","volume":"12","author":"de Leon","year":"2020","journal-title":"Asia Pac Psychiatry"},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ridd.2005.05.002","article-title":"Guidelines for the use of clozapine in individuals with developmental disabilities","volume":"27","author":"Sabaawi","year":"2006","journal-title":"Res Dev Disabil"},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1177\/0269881118783322","article-title":"Real-world effectiveness of clozapine for intellectual disability: results from a mirror-image and a reverse-mirror-image study","volume":"32","author":"Rohde","year":"2018","journal-title":"J Psychopharmacol"},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"Plos Med"},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40262-015-0236-8","article-title":"Reporting guidelines for clinical pharmacokinetic studies: the ClinPK Statement","volume":"54","author":"Kanji","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17512433.2017.1345623","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone","volume":"10","author":"Schoretsanitis","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/17512433.2018.1478727","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone","volume":"11","author":"Schoretsanitis","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/17512433.2018.1549489","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone","volume":"11","author":"Schoretsanitis","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0895-4356(96)00360-5","article-title":"Is meta-analysis a valid approach to the evaluation of small effects in observational studies?","volume":"50","author":"Shapiro","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/cap.1996.6.119","article-title":"Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia","volume":"6","author":"Schulz","year":"1996","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1089\/cap.2021.29213.bjc","article-title":"Clinical use of clozapine serum level and management of adverse effects in an adolescent with difficult to treat schizophrenia","volume":"31","author":"Bez","year":"2021","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00702-016-1573-y","article-title":"Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice","volume":"123","author":"Wohkittel","year":"2016","journal-title":"J Neural Transm (Vienna)"},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/104454602760219126","article-title":"Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine","volume":"12","author":"Alfaro","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"suppl B","key":"R62-20250603","first-page":"94","article-title":"Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response","volume":"55","author":"Piscitelli","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.rpsm.2022.06.003","article-title":"Clozapine for the treatment of pediatric encephalopathy associated with nonketotic hyperglycinemia","volume":"15","author":"Jim\u00e9nez-Fern\u00e1ndez","year":"2022","journal-title":"Revista de Psiquiatr\u00eda y Salud Ment"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-2007-979583","article-title":"Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high-performance liquid chromatography. Data from a prospective clinical trial","volume":"28","author":"Schulz","year":"1995","journal-title":"Pharmacopsychiatry"},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jadohealth.2006.05.022","article-title":"The use of oral contraceptives among Finnish teenagers from 1981 to 2003","volume":"39","author":"Hassani","year":"2006","journal-title":"J Adolesc Health"},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/17425255.2022.2106214","article-title":"Drug-drug interactions between psychotropic medications and oral contraceptives","volume":"18","author":"Schoretsanitis","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/oxfordjournals.schbul.a007143","article-title":"Caffeine intake in outpatients with schizophrenia","volume":"30","author":"Gurpegui","year":"2004","journal-title":"Schizophr Bull"},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.schres.2006.04.022","article-title":"Fewer but heavier caffeine consumers in schizophrenia: a case-control study","volume":"86","author":"Gurpegui","year":"2006","journal-title":"Schizophr Res"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2015.01.042","article-title":"Caffeine consumption in a long-term psychiatric hospital: tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use","volume":"164","author":"Arrojo-Romero","year":"2015","journal-title":"Schizophr Res"},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0278-5846(02)00348-2","article-title":"A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers","volume":"27","author":"de Leon","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.amepre.2018.12.007","article-title":"Trends in energy drink consumption among U.S. Adolescents and adults, 2003-2016","volume":"56","author":"Vercammen","year":"2019","journal-title":"Am J Prev Med"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"101587","DOI":"10.1016\/j.smrv.2021.101587","article-title":"Methodological review of caffeine assessment strategies with a focus on adolescents","volume":"62","author":"Meigs","year":"2022","journal-title":"Sleep Med Rev"},{"issue":"suppl 1","key":"R75-20250603","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JAD-2010-1379","article-title":"Caffeine and adenosine","volume":"20","author":"Ribeiro","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00004714-199408000-00014","article-title":"Interaction between caffeine and clozapine","volume":"14","author":"Vainer","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"R77-20250603","first-page":"175","article-title":"Clozapine levels and caffeine","volume":"57","author":"Odom-White","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1176\/appi.ps.55.5.491","article-title":"Atypical antipsychotic dosing: the effect of smoking and caffeine","volume":"55","author":"de Leon","year":"2004","journal-title":"Psychiatr Serv"},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12888-021-03199-x","article-title":"Caffeine-clozapine interaction associated with severe toxicity and multiorgan system failure: a case report","volume":"21","author":"Yartsev","year":"2021","journal-title":"BMC Psychiatry"},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"411","DOI":"10.24869\/psyd.2022.411","article-title":"Reflections on the complex history of the concept of clozapine-induced inflammation during titration","volume":"34","author":"de Leon","year":"2022","journal-title":"Psychiatr Danub"},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/FTD.0000000000000627","article-title":"Improving therapeutic decisions: pharmacodynamic monitoring as an integral part of therapeutic drug monitoring","volume":"41","author":"Shipkova","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.jcp.0000085405.08426.73","article-title":"Serum antimuscarinic activity during clozapine treatment","volume":"23","author":"de Leon","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2174\/138920011796504518","article-title":"Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients","volume":"12","author":"de Leon","year":"2011","journal-title":"Curr Drug Metab"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:05:26Z","timestamp":1748970326000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001154","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"2023-07-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}